AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01457352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo0921
Study NCT01352403 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux-en-Y gastric bypass
Study NCT01352403 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychotherapy-enhanced lifestyle intervention
Study NCT01028300 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ProDisc™-L Total Disc Replacement (TDR)
Description: The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
Study NCT02220088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAI of FOLFOX
Description: Retreatment with TAI: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT02220088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Accept sorafenib.
Study NCT01572090 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adjustment of oral antidiabetics/insulin therapy
Description: Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
Study NCT01572090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
Study NCT01572090 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en-Y gastric bypass
Description: Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Once daily application of platelet inhibiting medication
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Once daily application of platelet inhibiting medication
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Once daily application of lipid lowering medication
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Once daily application of lipid lowering medication
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Aspirin
Description: Once daily application of placebo
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Aspirin
Description: Once daily application of placebo
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Atorvastatin
Description: Once daily application of placebo
Study NCT03820466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Atorvastatin
Description: Once daily application of placebo
Study NCT02648880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise program
Description: Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation.
Study NCT02648880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
Study NCT02648880 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
Study NCT00987805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Banhasasim-tang
Description: Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
Study NCT00987805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn-starch granules
Description: This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
Study NCT01197339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: resonant voice
Description: A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
Study NCT02385656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 200mg of modafinil daily for 4 weeks
Study NCT01197339 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: voice rest
Description: A 4-hr voice rest will be prescribed to subjects following vocal loading.
Study NCT01762137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Flow Diversion
Description: Endovascular flow diverter placement
Study NCT01762137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coiling
Description: Endovascular coil placement
Study NCT00577616 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular repair
Description: Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
Study NCT03653559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home meals
Description: Adult participants with overweight or obesity are asked to consume home meals during 12 weeks.
Study NCT03653559 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy meals
Description: Adult participants with overweight or obesity are asked to consume healthy meals during 12 weeks.
Study NCT02547961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2-targeting CAR T Cells infusion
Description: HER-2-targeting CAR t cells infusion in breast cancer
Study NCT02660138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT02660138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT02660138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT02660138 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
Study NCT01757340 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss with normal protein and leucine intake
Description: Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
Study NCT01197339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathy voice
Description: A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
Study NCT01197339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation exercise
Description: A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
Study NCT01197339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resonant voice and relaxation exercise
Description: A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
Study NCT01757340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss with protein/leucine supplementation
Description: Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: workshop (Motivational intervention)
Description: Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Health talk
Description: Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
Study NCT01887262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCM-guided fluid management
Study NCT01887262 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluid management based on the clinical information alone
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Face to Face counseling
Description: Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Phone counseling
Description: Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS
Description: Use motivational interview strategies through telephone messages to provide smoking cessation intervention
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: SMS
Description: Use motivational interview strategies through telephone messages to provide smoking cessation intervention
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
Study NCT02659774 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Booklet
Description: A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
Study NCT03012126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight Clinic
Study NCT03012126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Weight and Your Child
Study NCT00895102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333 Tablet
Description: See Arm Description for more information.
Study NCT00895102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABT-333 Tablet
Description: See Arm Description for more information.
Study NCT00895102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: See Arm Description for more information.
Study NCT00895102 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Description for more information.
Study NCT00895102 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-333 Capsule
Description: See arm description for more information
Study NCT01295879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU's orally per week, for 8 weeks
Study NCT02264145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From HFA134a-MDI - low
Study NCT02264145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From HFA134a-MDI - medium
Study NCT02264145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From HFA134a-MDI - high
Study NCT02264145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanolic Solution From Respimat®
Study NCT00266786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketorolac Tromethamine
Description: Intranasal at 30mg
Study NCT00266786 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Placebo
Description: Intranasal Placebo
Study NCT02683590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ceramic Implant
Description: The replacement of the sternum by a ceramic implant
Study NCT02730793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Aztreonam
Description: Standard Therapy Comparator (Oral Cayston 75mg three times a day)
Study NCT02730793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Aztreonam
Description: Standard Therapy Comparator (Oral Cayston 75mg three times a day)
Study NCT02730793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Aztreonam
Description: Study Therapy (nasal Aztreonam 75mg twice per day)
Study NCT02730793 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Placebo
Description: Placebo (nasal saline twice per day)
Study NCT01185353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3009104
Description: Administered orally
Study NCT02238535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ventavis
Study NCT02238535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Study NCT00275561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Aerosolized swallowed fluticasone 880 mg twice a day
Study NCT00275561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhaler swallowed twice a day for 6 weeks
Study NCT02313831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval training
Description: Patients of this group will be submitted to an interval training program
Study NCT04087226 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTFE Retraction Cord
Description: Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
Study NCT04087226 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTFE Retraction Cord
Description: Polytetrafluoroethylene (PTFE) Retraction cord will be gently applied in gingival sulcus with minimal pressure. The intervention will be applied for three minutes in gingival sulcus, followed by a two stage addition silicone impression.
Study NCT03121391 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator withdrawal algorithm
Description: Steps and decision trees in the algorithm include in descending order:~Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor
Study NCT02093702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach
Study NCT02093702 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured Physical Activity and Exercise Education
Study NCT02617238 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular risk management based on PWV
Description: Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).~1. In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.~2. In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician
Study NCT01299766 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Description: BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
Study NCT01299766 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Therapy (ST)
Description: ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
Study NCT01662440 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies
Description: Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
Study NCT01662440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies
Description: Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
Study NCT01662440 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis
Description: Subjects received two doses of Japanese Encephalitis vaccine.
Study NCT01662440 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Japanese Encephalitis
Description: Subjects received two doses of Japanese Encephalitis vaccine.
Study NCT01662440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
Study NCT01662440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
Study NCT02257580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-Aminocaproic acid
Description: E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}